Halo Pharma and Altus Formulation in new formal collaboration

Published: 15-May-2013
Drug Delivery Research & Development Pharmaceutical

Combining strengths will enable companies to offer a full range of development and delivery options


Halo Pharma today has taken a minority ownership position in and established a formal collaboration with Quebec-based drug formulation and development company Altus Formulation. Altus uses proprietary technologies and approaches to solve pharmaceutical formulation and delivery problems.

Halo is focused on meeting development and manufacturing needs by offering solutions to scientific and technical challenges in the areas of pre-formulation, analytical method development, formulation, scale up, regulatory submission and commercial manufacturing. These approaches typically generate significant new wholly client owned IP.

With this new investment in, and association with, Altus Formulations, Halo takes a first step in offering an entire suite of proprietary scientific and technical solutions designed to solve intractable issues in such areas as drug solubility, bioavailability, tamper and abuse deterrence, and precisely managed drug dosage delivery. These proprietary solutions cover a wide range of non-sterile and sterile dosage forms.

‘We are delighted to have this new association with Altus as it will allow Halo to provide novel proprietary solutions to clients with difficult formulation problems in addition to those already available public domain and client originated solutions that we have historically offered,’ said CEO of Halo Pharma Clive Bennett.

  • Companies:
  • Halo Pharmaceutical
  • Altus Formulation
See more

You may also like

Drug Delivery

Recipharm and Altus offer new drug delivery for value added medicines

Read more
Recipharm, a contract development and manufacturing organisation, has signed a licensing agreement with Altus Formulation, a Canadian drug development company

Trending Articles

  1. Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
  2. Anton Paar expands Litesizer DIA Series with new models Introducing affordable and advanced solutions for particle analysis
  3. 2BScientific expands its life science product supply service to Europe with new German facility The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
  4. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  5. Five critical design elements for Pelton wheel turbine flowmeters Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Drug Delivery

Recipharm and Altus offer new drug delivery for value added medicines

Recipharm, a contract development and manufacturing organisation, has signed a licensing agreement with Altus Formulation, a Canadian drug development company
Manufacturing

Halo Pharmaceutical and ExxPharma to develop twin screw extrusion technology products

Twin screw extrusion is a highly versatile and precisely controlled continuous manufacturing process that utilises small mass mixing to improve efficiency, maximise quality and reduce costs
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now